These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9535194)

  • 1. Active drug substance impurity profiling part I. LC/UV diode array spectral matching.
    Nicolas EC; Scholz TH
    J Pharm Biomed Anal; 1998 Jan; 16(5):813-24. PubMed ID: 9535194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active drug substance impurity profiling part II. LC/MS/MS fingerprinting.
    Nicolas EC; Scholz TH
    J Pharm Biomed Anal; 1998 Jan; 16(5):825-36. PubMed ID: 9535195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of impurity profiles of drugs and related materials. Part 14: the role of HPLC/diode-array UV spectroscopy in the identification of minor components (impurities, degradation products, metabolites) in various matrices.
    Görög S; Bihari M; Csizér E; Dravetz F; Gazdag M; Herényi B
    J Pharm Biomed Anal; 1995 Dec; 14(1-2):85-92. PubMed ID: 8833970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
    Görög S
    Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of LC detection methods in the investigation of non-UV detectable organic impurities in a drug substance.
    McCrossen SD; Bryant DK; Cook BR; Richards JJ
    J Pharm Biomed Anal; 1998 Jul; 17(3):455-71. PubMed ID: 9656157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impurity Profile of Bronchodilators used in Asthma: A Critical Review.
    Prajapati KJ; Kothari CS
    Curr Drug Discov Technol; 2018; 15(4):272-304. PubMed ID: 28875855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate raw materials: HPLC methods for assay and purity and an NMR method for purity.
    Lacroix PM; Dawson BA; Sears RW; Black DB; Cyr TD; Ethier JC
    J Pharm Biomed Anal; 1998 Nov; 18(3):383-402. PubMed ID: 10096833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A digitized impurity database analysis method for determining the impurity profiles of gatifloxacin in bulk materials and injections.
    Dousheng Z; Yan C; Yaping L; Shangchen Y; Changqin H
    Pharmazie; 2012 Oct; 67(10):827-33. PubMed ID: 23136715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low level determination of 4-amino-2-ethoxy-cinnamic acid and its ethyl ester in a drug substance and its formulation prototypes by HPLC-UV-DAD.
    Soman A; Jacob S; Swanek F
    J Chromatogr Sci; 2009 Apr; 47(4):315-9. PubMed ID: 19406019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of impurity profiles of drugs and related materials: part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate.
    Babják M; Balogh G; Gazdag M; Görög S
    J Pharm Biomed Anal; 2002 Aug; 29(6):1153-7. PubMed ID: 12110402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Identification of impurity peaks in the HPLC chromatogram by LC-MS and two-dimensional chromatographic correlation spectroscopy].
    Chen ZZ; Zhang DS; Wang N; Feng F; Hu CQ
    Yao Xue Xue Bao; 2012 Apr; 47(4):492-7. PubMed ID: 22799032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
    Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of ipriflavone and its synthetic impurities by high-performance liquid chromatography using diode-array detection.
    Sustacha K; Chacón M; Lucero ML; Orjales A
    J Chromatogr A; 1996 Jan; 719(1):245-50. PubMed ID: 8589833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated peak tracking for comprehensive impurity profiling in orthogonal liquid chromatographic separation using mass spectrometric detection.
    Xue G; Bendick AD; Chen R; Sekulic SS
    J Chromatogr A; 2004 Oct; 1050(2):159-71. PubMed ID: 15508308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high pH based reversed-phase high performance liquid chromatographic method for the analysis of aminoglycoside plazomicin and its impurities.
    Tan L; Wlasichuk KB; Schmidt DE; Campbell RL; Hirtzer P; Cheng L; Karr DE
    J Pharm Biomed Anal; 2012 Jul; 66():75-84. PubMed ID: 22459505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation, synthesis and characterization of impurities in celecoxib, a COX-2 inhibitor.
    Satyanarayana U; Rao DS; Kumar YR; Babu JM; Kumar PR; Reddy JT
    J Pharm Biomed Anal; 2004 Jun; 35(4):951-7. PubMed ID: 15193741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative impurity profiling by principal component analysis of high-performance liquid chromatography-diode array detection data.
    Wiberg K
    J Chromatogr A; 2006 Mar; 1108(1):50-67. PubMed ID: 16430906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification, Characterization, Synthesis and Quantification of Related Impurities of Liguzinediol.
    Cheng D; Zhou Y; Li W; Shan CX; Chai C; Cui XB; Kang B; Wang TL; Wen HM
    J Chromatogr Sci; 2015 Sep; 53(8):1280-8. PubMed ID: 25680683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of potential impurities of rabeprazole sodium.
    Reddy GM; Bhaskar BV; Reddy PP; Sudhakar P; Babu JM; Vyas K; Reddy PR; Mukkanti K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1262-9. PubMed ID: 17134865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.